Adverse effects · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
1 finding from 1 review
Colchicine was associated with statistically significantly more adverse effects than prednisolone (nine participants reporting adverse effects on colchicine versus two on prednisolone).
1 study · 34 participants
GRADE not reported
Recurrence · Participants with a previous or current history of recurrent aphthous stomatitis (RAS), diagnosed on history and clinical examination;…
Colchicine (0.5 mg per day for 3 months) showed no clear difference in recurrence during treatment period compared with prednisolone (5 mg per day for 3 months); GRADE not reported.
1 finding from 1 review
FEV1 % predicted · children and adolescents with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FVC · children and adolescents with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Growth and nutritional status · children and adolescents with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of infective pulmonary exacerbations: number of exacerbations per patient year · children and adolescents with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Isolation of other micro‐organisms from the respiratory tract: number of positive cultures per patient year · children and adolescents with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects of antibiotics: number of participants reporting a serious adverse event · children and adolescents with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: clinically important change in global state · patients with schizophrenia
1 finding from 1 review
Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia
1 finding from 1 review
Adverse effect: clinically important adverse effect (weight ‐ BMI) · patients with schizophrenia
1 finding from 1 review
Service use: time to hospitalisation · patients with schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Mental state: clinically important response, as defined by individual studies * · patients with schizophrenia
1 finding from 1 review
Functioning: clinically important change in general functioning, as defined by individual studies · patients with schizophrenia
1 finding from 1 review
Adverse effect: clinically important adverse effect (weight ‐ BMI) · patients with schizophrenia
1 finding from 1 review
Service use: time to hospitalisation · patients with schizophrenia
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
1 finding from 1 review
Global state: clinically important change in global state · patients with schizophrenia
1 finding from 1 review
Mental state: clinically important response, as defined by individual studies * · patients with schizophrenia
1 finding from 1 review